BNP Paribas Financial Markets’s Aktis Oncology AKTS Stock Holding History

BNP Paribas Financial Markets’s Portfolio AKTS Stock Details AKTS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$80.1K	Buy	+4,480	New	+$87K	﹤0.01%	4479

Other funds holding AKTS

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BNP Paribas Financial Markets's AKTS Position: Q1 2026 in Review

BNP Paribas Financial Markets opened a new position in Aktis Oncology (AKTS) in Q1 2026: 4,480 shares worth $80.1K. The stake represents ﹤0.01% of the portfolio and ranks #4479 among its holdings.

69 funds tracked by Wall St. Rank hold AKTS as of Q1 2026.

BNP Paribas Financial Markets held 4,480 shares of Aktis Oncology worth $80.1K as of Q1 2026.
Aktis Oncology was a new BNP Paribas Financial Markets position in Q1 2026.
Aktis Oncology made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q1 2026, its #4479 holding.
69 funds tracked by Wall St. Rank held Aktis Oncology as of Q1 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.